10-QPeriod: Q1 FY2025

QUEST DIAGNOSTICS INC Quarterly Report for Q1 Ended Mar 31, 2025

Filed April 23, 2025For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) reported its first quarter 2025 results with a notable increase in net revenues, primarily driven by recent acquisitions and organic growth within its Diagnostic Information Services (DIS) segment. Net revenues grew by 12.1% year-over-year, reaching $2.65 billion. The company demonstrated improved operating income and net income, with diluted earnings per share (EPS) rising to $1.94 from $1.72 in the prior year's quarter. Cash flow from operations saw a significant increase, highlighting improved working capital management and higher operating income. While the company repaid $600 million in senior notes, it also utilized its secured receivables credit facility for new borrowings. Management remains confident in the company's liquidity and ability to fund future operations, capital expenditures, and growth initiatives.

Financial Highlights

55 data points
Beta

Revenue

$2.65B

32.5% Gross Margin

Net Income

$220.00M

8.3% Net Margin

EPS (Diluted)

$1.94

Total Assets

$15.80B

Cash & Equivalents

$188.00M

Free Cash Flow

$197.00M

Financial Statements
Beta
Revenue$2.65B
Cost of Revenue$1.79B
Gross Profit$863.00M
SG&A Expenses$476.00M
Operating Expenses$2.31B
Operating Income$346.00M
Net Income$220.00M
EPS (Basic)$1.97
EPS (Diluted)$1.94
Shares Outstanding (Basic)111.00M
Shares Outstanding (Diluted)113.00M

Key Highlights

  • 1Net revenues increased by 12.1% to $2.65 billion in Q1 2025, driven by a 12.7% rise in DIS revenues, largely due to recent acquisitions contributing approximately 10% to DIS revenue.
  • 2Requisition volume increased by 12.4%, with acquisitions contributing 13.3%, while organic volume slightly decreased by 0.9%.
  • 3Revenue per requisition saw a modest increase of 0.3% year-over-year, influenced by an increase in tests per requisition, though partially offset by acquisitions with lower revenue per requisition.
  • 4Operating income grew by 15.4% to $346 million, and net income attributable to Quest Diagnostics increased by 13.2% to $220 million.
  • 5Diluted earnings per share (EPS) rose to $1.94 in Q1 2025, up from $1.72 in Q1 2024, reflecting improved profitability.
  • 6Net cash provided by operating activities significantly increased to $314 million from $154 million in the prior year period, indicating improved cash generation.
  • 7The company repaid $600 million in senior notes that matured in March 2025 and also borrowed $215 million under its secured receivables credit facility.

Frequently Asked Questions

The substantial increase in net revenues was primarily driven by the impact of recent acquisitions, which contributed significantly to the Diagnostic Information Services (DIS) segment's revenue. Organic growth also played a role, though acquisitions were the larger contributor.

Quest Diagnostics repaid its $600 million in senior notes that matured in March 2025. To manage liquidity and fund operations, the company also borrowed $215 million under its secured receivables credit facility.

The company reported a strong increase in net cash provided by operating activities, rising to $314 million from $154 million in the prior year's quarter. This improvement was attributed to the timing of payments and increased operating income, suggesting a positive trend in cash generation.

The company continues to focus on its 'Invigorate' program, which aims to drive cost savings and productivity improvements across its operations through automation and AI. The report also mentions a multi-year project called 'Project Nova' to modernize its 'Order-to-Cash' business processes.